Molecular Vision: Paine, Mol Vis 2012; 18:2749-2757. Table 2

Table 2. Genotypic/Allelic Difference between cases and controls.

dBSNP	Genotype	PDR n=253(%)	DC n=240(%)	OR(95%CI)	P
rs833061	TT	152(60.07)	167(69.58)	Ref
	CT	81(32.01)	67(27.91)	1.32 (0.88–2.003)	0.16
	CC	20(7.92)	6(2.5)	3.66(1.35–11.4)	0.004*
	T	385(76.08)	401(83.54)	Ref
	C	121(23.92)	79(16.46)	1.59(1.15–2.21)	0.004*
	CC	172(67.98)	153(63.75)	Ref
rs1800469	CT	70(27.66)	73(30.41)	0.85(0.56–1.28)	0.48
	TT	11(4.34)	14(5.83)	0.69(0.27–1.71)	0.41
	C	414(81.81)	379(78.95)	Ref
	T	92(18.19)	101(21.05)	0.83(0.6–1.15)	0.26
	AA	109(43.08)	131(54.58)	Ref
rs2430561	AT	111(43.87)	96(40)	1.38(0.94–2.05)	0.08
	TT	33(13.04)	13(5.42)	3.05(1.47–6.62)	0.001*
	A	329(65.01)	358(74.58)	Ref
	T	177(34.99)	122(25.42)	1.58(1.88–2.09)	0.001*

*Significant p value after Bonferroni correction (i.e., the adjusted p value at the 0.05 significance level is 0.016. Allele C (rs833061), T (rs1800469), and T (rs2430561 are responsible for increased production of these cytokines and are considered as risk allele. Hence, the TT, CC and AA genotypes and T, C, and A alleles of rs833061, rs1800469 and rs2430561, respectively, are considered as reference genotype and allele.